A potential therapeutic effect of catalpol in Duchenne muscular dystrophy revealed by binding with TAK1

BACKGROUND: Duchenne muscular dystrophy (DMD) is a progressive muscle disease caused by the loss of dystrophin, which results in inflammation, fibrosis, and the inhibition of myoblast differentiation in skeletal muscle. Catalpol, an iridoid glycoside, improves skeletal muscle function by enhancing m...

Descripción completa

Detalles Bibliográficos
Autores principales: Xu, Dengqiu, Zhao, Lei, Jiang, Jingwei, Li, Sijia, Sun, Zeren, Huang, Xiaofei, Li, Chunjie, Wang, Tao, Sun, Lixin, Li, Xihua, Jiang, Zhenzhou, Zhang, Luyong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7567147/
https://www.ncbi.nlm.nih.gov/pubmed/32869445
http://dx.doi.org/10.1002/jcsm.12581

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7567147/
https://www.ncbi.nlm.nih.gov/pubmed/32869445
http://dx.doi.org/10.1002/jcsm.12581

Ejemplares similares